Pulmonary lymphangioleiomyomatosis (LAM): Progress and current challenges
- 31 May 2007
- journal article
- review article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 103 (2), 369-382
- https://doi.org/10.1002/jcb.21419
Abstract
Lymphangioleiomyomatosis (LAM), a rare lung disease, is characterized by the progressive proliferation, migration, and differentiation of smooth muscle (SM)‐like LAM cells, which lead to the cystic destruction of the lung parenchyma, obstruction of airways and lymphatics, and loss of pulmonary function. LAM is a disease predominantly affecting women and is exacerbated by pregnancy; only a lung transplant can save the life of a patient. It has been discovered that in LAM, somatic or genetic mutations of tumor suppressor genes tuberous sclerosis complex 1 (TSC1) or TSC2 occur and the TSC1/TSC2 protein complex functions as a negative regulator of the mTOR/S6K1 signaling pathway. These two pivotal observations paved the way for the first rapamycin clinical trial for LAM. The recent discoveries that TSC1/TSC2 complex functions as an integrator of signaling networks regulated by growth factors, insulin, nutrients, and energy heightened the interest regarding this rare disease because the elucidation of disease‐relevant mechanisms of LAM will promote a better understanding of other metabolic diseases such as diabetes, cancer, and cardiovascular diseases. In this review, we will summarize the progress made in our understanding of TSC1/TSC2 cellular signaling and the molecular mechanisms of LAM; we will also highlight some of the lesser explored directions and challenges in LAM research. J. Cell. Biochem. 103: 369–382, 2008.Keywords
This publication has 78 references indexed in Scilit:
- Molecular Pathogenesis of LymphangioleiomyomatosisAmerican Journal of Respiratory Cell and Molecular Biology, 2007
- Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activityGenes & Development, 2006
- Role of FIP200 in cardiac and liver development and its regulation of TNFα and TSC–mTOR signaling pathwaysThe Journal of cell biology, 2006
- mTOR and cancer: insights into a complex relationshipNature Reviews Cancer, 2006
- Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioningThe Journal of cell biology, 2006
- Statins and cancer preventionNature Reviews Cancer, 2005
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR ComplexScience, 2005
- Pam and Its Ortholog Highwire Interact with and May Negatively Regulate the TSC1·TSC2 ComplexPublished by Elsevier BV ,2004
- Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosisJournal of Human Genetics, 2002
- A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancerNature Genetics, 1995